Phase 3 — Large-scale testing across thousands of people, comparing the new treatment against current standard treatments.
Trial locations(191 sites)
United States
Site 164, Mobile, Alabama Site 36, La Jolla, California Site 27, Los Angeles, California Site 16, Palo Alto, California Site 19, Newark, Delaware Site 108, Washington D.C., District of Columbia Site 14, Fort Myers, Florida Site 48, Orlando, Florida Site 21, St. Petersburg, Florida Site 20, West Palm Beach, Florida Site 171, Atlanta, Georgia Site 50, Chicago, Illinois Site 2, Louisville, Kentucky Site 162, Baton Rouge, Louisiana Site 155, Minneapolis, Minnesota Site 168, St Louis, Missouri Site 94, Hackensack, New Jersey Site 6, Albuquerque, New Mexico Site 113, Durham, North Carolina Site 118, Winston-Salem, North Carolina Site 191, Cleveland, Ohio Site 43, Philadelphia, Pennsylvania Site 153, Philadelphia, Pennsylvania Site 154, Philadelphia, Pennsylvania Site 89, Chattanooga, Tennessee Site 115, Memphis, Tennessee Site 88, Nashville, Tennessee Site 17, Sugarland, Texas Site 10, Salt Lake City, Utah Site 12, Blacksburg, Virginia Site 23, Norfolk, Virginia Australia
Site 11, Blacktown, New South Wales Site 24, St Leonards, New South Wales Site 166, Greenslopes, Queensland Site 151, Melbourne, Victoria Brazil
Site 149, Rio de Janeiro, Rio de Janeiro France
Site 64, Vandœuvre-lès-Nancy Greece
Site 117, Heraklion, Crete Japan
Site 167, Nagoya, Aichi-ken Site 185, Fukuoka, Fukuoka Site 127, Hiragi, Kagawa-ken Site 174, Natori-shi, Miyagi Site 125, Ōsaka-sayama, Osaka Site 188, Minato-Ku, Tokyo Thailand
Site 114, Bangkok Noi, Bangkok Site 107, Pathum Wan, Bangkok Site 65, Ratchathewi, Bangkok Site 146, Chiang Rai, Changwat Chiang Rai Site 77, Hat Yai, Changwat Songkhla United Kingdom
Site 177, Newcastle upon Tyne